Shares of Arcus Biosciences (RCUS) after moving lower after Roche (RHHBY) announced yesterday that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq and chemotherapy versus pembrolizumab and chemotherapy as an initial treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints. The concept of Roche’s study is similar to Arcus and Gilead’s (GILD) Phase 3 STAR-121 in first-line non-small cell lung cancer, Cantor Fitzgerald analyst Li Watsek said in a research note. The analyst says Roche’s outcome is likely the worst-case scenario for Arcus and could add uncertainty to its STAR-121 study. Shares of Arcus Biosciences are down 6% to $13.54 in premarket trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences price target lowered to $44 from $50 at Truist
- Arcus completes enrollment for domvanalimab study for GI cancer
- Arcus Biosciences Advances Gastrointestinal Cancer Treatment
- Arcus Biosciences price target raised to $38 from $36 at Citi
- Gilead, Arcus announce new data from Cohort B of ARC-9 mCRC study